Physician's Weekly7d
PD-1/PD-L1 Inhibitors With Chemotherapy vs. Platinum-Based Treatment in Advanced Urothelial Cancer
The following is a summary of “Efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination therapy versus platinum-based chemotherapy as a first-line treatment of advanced urothelial cancer ...
EurekAlert!15d
Ability of large language models to extract PD-L1 biomarker details from electronic health records
A new study, published in the peer-reviewed journal AI in Precision Oncology, examines the ability of large language models ...
Business Wire5d
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patient…
Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...
The American Journal of Managed Care15d
First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1
Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1.
Precision Medicine Online15d
FDA Approves BeiGene's Tevimbra in First-Line PD-L1-Positive Esophageal Cancers
Patients with PD-L1-positive tumors lived more than seven months longer on Tevimbra added to chemotherapy compared to just chemo.
Finely tuned large language models can extract PD-L1 biomarker details from electronic health records
A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract PD-L1 biomarker details from an electronic health record (EHR).